I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 0, missing the estimate of USD 706.25 K.
EPS: As of FY2026 Q2, the actual value is USD -1.45, missing the estimate of USD -1.34.
EBIT: As of FY2026 Q2, the actual value is USD -28.71 M.
Net Loss
Keros Therapeutics, Inc. reported a net loss of - $28.7 million in the second quarter of 2026, which is a decrease of $2.0 million compared to a net loss of - $30.7 million in the second quarter of 2025, primarily due to revenue recognized in 2025 from a license agreement with Takeda and decreased research and development efforts. For the six months ended June 30, 2026, the company recorded a net loss of - $52.418 million, contrasting with a net income of $117.755 million for the same period in 2025.
Research and Development Expenses
Research and development expenses for the second quarter of 2026 were - $22.3 million, a decrease of - $21.2 million from - $43.5 million in the same period of 2025. This reduction was mainly due to the transition of elritercept-related expenses to Takeda and a corporate restructuring completed in 2025. For the six months ended June 30, 2026, R&D expenses totaled - $38.428 million, compared to - $92.212 million for the corresponding period in 2025.
General and Administrative Expenses
General and administrative expenses were - $8.6 million for the second quarter of 2026, marking a decrease of - $5.9 million from - $14.5 million in the second quarter of 2025. This decrease resulted primarily from lower professional fees and compensation costs following the 2025 corporate restructuring. For the six months ended June 30, 2026, G&A expenses were - $18.753 million, compared to - $24.979 million for the same period in 2025.
Cash and Cash Equivalents
As of June 30, 2026, Keros Therapeutics, Inc. held $257.6 million in cash and cash equivalents, a decrease from $287.4 million reported on December 31, 2025.
Total Revenue
Total revenue for the second quarter of 2026 was - $0, a significant decrease from $18.168 million in the second quarter of 2025. For the six months ended June 30, 2026, total revenue was $367, compared to $229.414 million for the same period in 2025.
Outlook / Guidance
Keros Therapeutics, Inc. anticipates that its cash and cash equivalents as of June 30, 2026, will fund operating expenses and capital expenditure requirements into the first half of 2028. The company also expects to present initial data from the Phase 2 clinical trial of rinvatercept in Duchenne muscular dystrophy patients in the first half of 2027.